With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.
A mixture of methyl 6-(5′-bromo-2′-hydroxy-2-biphenylyl)-2-pyridinecarboxylate (200mg, 0.52mmol), tetrahydro-2H-pyran-4-ylmethyl-4-methylbenzene sulphonate (430mg, 1.5mmol) and potassium cabonate (200mg) in dimethylformamide (4ml) was heated to reflux for 3 hours under nitrogen. The reaction mixture was then filtered through celite, washed with ethyl acetate (10mls) and evaporated to an oil which was flash chromatographed eluting with diethyl ether/isohexane (1/5). The product was dissolved in methanol (10ml), treated with 2N sodium hydroxide (2ml) and heated at 70C for 15min. The solution was evaporated and partitioned between water and ethyl acetate. After drying with anhydrous sodium sulphate the ethyl acetate solution was evaporated to give the title compound (130mg). LC/MS [M+H] 470.3, 471.4, Rt=3.65min., 101691-65-0
As the paragraph descriping shows that 101691-65-0 is playing an increasingly important role.
Reference£º
Patent; GLAXO GROUP LIMITED; WO2005/108369; (2005); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics